Bronchodilator Drugs - Estonia | Statista Market Forecast

The market for Bronchodilator Drugs market in Estonia is expected to witness a significant growth in revenue, with projections indicating that it will reach US$5.83m in 2024.
This growth is further expected to continue at a compounded annual growth rate (CAGR) of 3.87% from 2024 to 2029.
By 2029, the market volume is forecasted to reach US$7.04m.
When compared globally, it is worth noting that United States is anticipated to generate the highest revenue in the Bronchodilator Drugs market, with an estimated revenue of US$17.34bn in 2024.
Estonia's bronchodilator drugs market is witnessing a surge in demand due to the country's high prevalence of respiratory diseases and increasing awareness about the importance of respiratory health.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are an essential part of the treatment of respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). In Estonia, the market for bronchodilator drugs has been growing steadily in recent years.

Customer preferences: Patients suffering from respiratory diseases in Estonia prefer bronchodilator drugs that are effective and affordable. They also prefer drugs that have fewer side effects and are easy to administer. As a result, there is a high demand for generic bronchodilator drugs in the market.

Trends in the market: The Estonian market for bronchodilator drugs has been growing due to the increasing prevalence of respiratory diseases in the country. The aging population and the high prevalence of smoking are the major contributing factors to the rise in respiratory diseases. Furthermore, the increasing awareness about respiratory diseases and the availability of advanced treatment options are also driving the demand for bronchodilator drugs in Estonia.

Local special circumstances: The Estonian healthcare system is highly decentralized, with a significant role played by private healthcare providers. As a result, the availability and affordability of bronchodilator drugs vary across the country. The government is taking steps to improve the availability and affordability of essential medicines, including bronchodilator drugs, in the country.

Underlying macroeconomic factors: The Estonian economy has been growing steadily in recent years, driven by strong domestic demand and a favorable business environment. The healthcare sector has also been growing, with increasing investments in healthcare infrastructure and services. These macroeconomic factors are likely to support the growth of the bronchodilator drug market in Estonia in the coming years.In conclusion, the market for bronchodilator drugs in Estonia is growing steadily due to the increasing prevalence of respiratory diseases, the availability of advanced treatment options, and the favorable macroeconomic environment. However, the availability and affordability of these drugs vary across the country, and the government is taking steps to address these issues.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.